SASara Assadiasl

Sara Assadiasl

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sara Assadiasl has a total of 102 co-authors. Here are the top co-authors by number of shared publications:

  • Mohammad Hossein Nicknam

    Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    15 shared publications
  • Mohammad Hossein Nicknam

    Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran

    13 shared publications
  • Narjes Soleimanifar

    Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran

    10 shared publications
  • Hanieh Mojtahedi

    Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran

    8 shared publications
  • Narjes Soleimanifar

    Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran

    8 shared publications
  • Mahboobeh Freidoon

    Department of Nephrology, Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    7 shared publications

Latest Publications

  • Increased levels of soluble TNF-R1 and serum amyloid A in patients with diabetic nephropathy

    by Mahboobeh Freidoon, Sara Assadiasl, Hadi Kazemzadehghadim, Naghmeh Sayadi, Narjes Soleimanifar, Sepehr Safdel, Maryam Sadr, Hanieh Mojtahedi, Pedram Chezanisharahi, Mohammad Hossein Nicknam

  • Association of HLA alleles and mismatches with post-transplant lymphoproliferative disorder in solid organ transplant recipients: a systematic review and meta-analysis

    by Sara Assadiasl, Mahdi Yazdani, Hanieh Mojtahedi, Sepehr Safdel, Somayeh Mami, Maryam Sadr, Ahmadreza Sadeghi, Narjes Soleimanifar, Mohammad Hossein Nicknam


  • Open Access

    Association of Janus kinase 1 and 2 expression with clinical indices in diabetic kidney disease

    by Mahboobeh Freidoon, Naghmeh Sayadi, Sara Assadiasl, Hadi Kazemzadehghadim, Narjes Soleimanifar, Maryam Sadr, Hanieh Mojtahedi, Maryam Ahmadi, Mohammad Hossein Nicknam

    Background: Diabetic Kidney Disease (DKD) is a prevalent complication of uncontrolled hyperglycemia that imposes a considerable burden on the health system due to the need for renal replacement therapy in the long term. Therefore, early diagnosis and prevention of renal damage in diabetic patients is critical. In the present study, we investigated the expression level of Janus kinase (Jak) 1, 2, and 3 genes, which play a role in the signal transduction of inflammatory cytokines and growth factors, for therapeutic or diagnostic purposes. Materials and Methods: Sixty patients with DKD, 60 diabetic patients without nephropathy, and 60 healthy individuals were recruited, and the expression level of the Jak1, Jak2, and Jak3 genes was evaluated using real-time polymerase chain reaction in peripheral blood mononuclear cells. Results: The results showed that Jak1 and Jak2 gene expression was significantly upregulated in DKD patients compared to healthy controls ( P values: 0.02 and 0.002, respectively). A significant negative correlation was observed between the expression of Jak1 and 2 genes and glomerular filtration rate in patients ( P values: 0.047 and 0.03, respectively). There was also a positive correlation between the urine albumin-creatinine ratio of the DKD group with Jak1 and 2 gene expression levels ( P values: 0.008 and 0.015, respectively). Moreover, receiver operating characteristic curve analysis showed a fair diagnostic value for Jak2 expression in DN (0.71, 95% confidence interval: 0.59–0.834 [ P = 0.002]). Conclusion: Gene expression evaluation showed an increased expression of Jak1 and Jak2 in DKD, suggesting Jak1/2 inhibition for the treatment of patients. In addition, Jak2 expression might have diagnostic or predictive value in diabetes.

  • Open Access

    Association of interleukin-8 and neutrophil-to-lymphocyte ratio with clinical indices in diabetic nephropathy

    by Mahboobeh Freidoon, Hadi Kazemzadehghadim, Sara Assadiasl, Naghmeh Sayadi, Narjes Soleimanifar, Maryam Sadr, Hanieh Mojtahedi, Mohammad Hossein Nicknam

    Diabetic nephropathy (DN) is the most prevalent reason for chronic kidney diseases that end up with renal failure if it is not diagnosed and treated at early stages. Therefore, low-cost, non-invasive, and easy-to-use tests are necessary for efficient follow-up and early diagnosis of DN in diabetic patients. Interleukin-8 (IL-8) as the main recruiter of neutrophils may play a role in inflammatory responses that end up with renal damage and dysfunction in DN. In a case-control study, serum levels of IL-8 and neutrophil-to-lymphocyte ratios (NLR) were evaluated in correlation with clinical findings in 60 patients with DN, 60 type 2 diabetic patients without renal involvement, and 60 age and sex-matched healthy subjects. IL-8 levels were significantly higher in diabetic nephropathy patients than in diabetic patients without nephropathy and healthy controls (both p-value<0.0001). However, the frequency of neutrophils in both groups of patients was higher than that of healthy individuals. Despite increased NLRs in diabetic patients, the difference was only significant between DN and healthy groups (P-value: 0.03). A direct correlation was observed between IL-8 levels and NLR (P-value: 0.02), and a negative correlation between IL-8 and eGFR (P-value: 0.01). In addition, UACR was associated with IL-8 concentrations (P-value: 0.04) in DN patients. IL-8 level showed a higher diagnostic value for diabetic nephropathy [AUC: 0.87 (p<0.0001)] than NLR and neutrophil count. Increased level of IL-8 in DN is associated with elevated NLR and UACR, and reduced eGFR. Therefore, IL-8 levels might be considered a diagnostic or prognostic biomarker for DN.

  • Open Access

    Heart Transplantation: Immunological Challenges Revisited

    by Sara Assadiasl, Sepehr Safdel, Mahsa Gheitasi, Mohammad Hossein Nicknam

    Introduction: Immunologic responses to cardiac allografts initiate before transplantation during brain-dead organ procurement and might persist for years after transplantation, culminating in chronic allograft dysfunction. Despite remarkable advances in post-transplant care and immunosuppressive agents, acute cellular and antibody-mediated rejections as well as chronic allograft vasculopathy significantly affect cardiac allograft and patient survival. Methods: Herein, recent findings of the molecular mechanisms involved in the inflammatory responses before and after heart transplantation, including brain death donor inflammation, acute cellular rejection, antibody-mediated rejection, and chronic allograft dysfunction, have been summarized, along with novel therapeutic approaches for their treatment. Finally, recent developments in prognostic and diagnostic biomarkers for immunological complications have been provided, with an overview of the most promising biomarkers to date. Results and Discussion: Due to the recent developments in the description of molecular mechanisms involved in the immunopathogenesis of cardiac allograft rejection, some immune cells, proinflammatory cytokines, and adhesion molecules have been proposed as therapeutic targets for the prevention or treatment of alloimmune responses. In addition, several molecules derived from graft tissue or immune cells, e.g. natriuretic peptides, cardiac troponins, exosomal products, microRNAs, and donor-derived cell-free DNA, have been suggested as potential biomarkers for the prediction or diagnosis of cardiac transplant rejection. Conclusion: Considering the need to design non-invasive, low-cost tests for early diagnosis of post-transplant complications and convenient follow-up of the cardiac transplant recipients, peripheral blood biomarkers could be appropriate candidates for this purpose.


  • Endoplasmic reticulum aminopeptidase 1 gene expression and serum angiotensin II levels associated with developing nephropathy in type2 diabetes patients

    by Sepehr Safdel, Sara Assadiasl, Mahboobeh Freidoon, Hanieh Mojtahedi, Mahsa Gheitasi, Maryam Sadr, Hadi Kazemzadehghadim, Narjes Soleimanifar, Mohammad Hossein Nicknam

    Purpose Diabetic nephropathy (DN) is the main cause of end-stage renal disease. The renin-angiotensin system and inflammatory pathways are suggested to contribute to renal injuries in diabetes. Endoplasmic reticulum aminopeptidase 1 (ERAP1) breaks Ang II into less harmful derivatives. This study aimed to investigate the expression level of ERAP1 and TLR4 genes in association with serum Ang II in DN patients. Methods In 80 type 2 diabetic (T2DM) patients with nephropathy, 80 T2DM patients without nephropathy, and 60 healthy controls, polymorphisms of the ERAP1 gene (rs28096, rs34750, rs26653, rs3734016, and rs30187), as well as ERAP1 and TLR4 gene expression were evaluated with RT-PCR. Serum Ang II level was quantified using ELISA. Results Serum Ang II levels were significantly higher in DN patients compared to T2DM patients without nephropathy and healthy controls (P-values: 0.012 and 0.006, respectively). ERAP1 expression was also enhanced in the DN group compared to T2DM and healthy individuals (P-value: 0.033 and 0.017, respectively), and showed a significant association with Ang II levels [R: 0.43, R2: 0.184 (p-value = 0.02)]. In both patient groups, TLR4 expression was increased compared to healthy controls (P-value: 0.003 and 0.004). ERAP1 rs30187 TT was more frequent in the DN group (P-value 0.021). Conclusion Increased levels of Ang II and enhanced expression of ERAP1 might be prognostic of developing nephropathy in T2DM patients.

  • Immunological Approaches in the Treatment of Diabetic Nephropathy

    by Fatemeh Pour-Reza-Gholi, Sara Assadiasl

    : Diabetic nephropathy (DN), the leading cause of end-stage renal disease, has no definite treatment so far. In fact, a combination of metabolic, hemodynamic, and immunological factors are involved in the pathogenesis of DN; therefore, effective disease management requires a holistic approach to all predisposing contributors. Due to the recent findings about the role of inflammation in the initiation and progression of kidney injury in diabetic patients and considerable advances in immunotherapy methods, it might be useful to revise and reconsider the current knowledge of the potential of immunomodulation in preventing and attenuating DN. In this review, we have summarized the findings of add-on therapeutic methods that have concentrated on regulating inflammatory responses in diabetic nephropathy, including phosphodiesterase inhibitors, nuclear factor-kB inhibitors, Janus kinase inhibitors, chemokine inhibitors, anti-cytokine antibodies, cell therapy, and vaccination.


  • Open Access

    A Review of Senolytic Drugs in Reducing the Biological Problems of Aging

    by Sara Assadiasl, Sepehr Safdel, Mohammad Hossein Nicknam

    Objectives: Considering the increase in the old adult population and age-related disorders there is a need for strategies to reduce the complications of aging. Senolytic drugs might improve the function of tissues and organs in elderly people by destroying senescent cells. In this review, we aimed to introduce different categories of ...

  • Intestinal transplantation: Significance of immune responses

    by Sara Assadiasl, Mohammad Hossein Nicknam


  • Open Access

    Upregulated Expression of Janus Kinase Genes in T Cell-Mediated Acute Kidney Allograft Rejection

    by Mahboobeh Freidoon, Fatemeh Pour-Reza-Gholi, Sara Assadiasl, Azam Alamdari, Narjes Soleimanifar, Maryam Sadr, Hanieh Mojtahedi, Mohammad Hossein Nicknam

    Background: T-cell-mediated acute kidney transplant rejection (TCMR) is a post-transplantation complication characterized by the infiltration of immune cells into the tissue and sudden dysfunction of the allograft. To develop effective diagnostic and therapeutic methods, it is crucial to understand the molecular mechanisms involved in the initiation and progression of TCMR. Janus kinase (JAK) enzymes, which are involved in proinflammatory cytokine signal transduction, may play a role in TCMR. Given the recent development of JAK inhibitors, the role of JAK molecules should be explored to determine whether they could be potential targets for the treatment of TCMR. Objectives: The study aimed to compare the relative expression of JAK-1, JAK-2, and JAK-3 genes between patients diagnosed with TCMR and stable recipients. Methods: The expression of JAK-1, JAK-2, and JAK-3 genes was evaluated in peripheral blood monocytes of 30 patients with TCMR and 30 stable patients using the RT-PCR method. Results: Janus kinase-1 gene expression in TCMR patients was significantly higher compared to stable patients (P-value = 0.02). However, the relative expression of JAK-2 and JAK-3 genes was comparable between the two groups. Additionally, there was a negative correlation between JAK-1 and JAK-3 gene expression and the estimated glomerular filtration rate in the studied population (P-value = 0.01 and 0.029, respectively). Conclusions: Janus kinase-1 gene expression increased significantly during TCMR of the kidney transplant. Therefore, specific inhibition of this molecule by JAK inhibitor drugs might be considered a therapeutic option for treating TCMR.